Ljunggren H G, Ohlén C, Höglund P, Yamasaki T, Klein G, Kärre K
Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden.
J Immunol. 1988 Jan 15;140(2):671-8.
H-2-deficient variants, selected from the murine lymphoma RBL-5, were recently shown to be less tumorigenic in syngeneic mice compared with the corresponding H-2-positive wild-type cell line. The present study focused on the detailed cellular interactions leading to the specific rejection of H-2-deficient cells in vivo. In vivo experiments with mixed tumor inocula, measuring either tumor outgrowth or rapid elimination, showed that the presence of H-2-positive lymphoma cells did not suppress the rejection of H-2-deficient cells. Conversely, H-2-deficient cells did not activate a rejection of H-2-positive cells. H-2-deficient cells were selectively eliminated even when they were present in a 10-fold excess compared with the H-2-positive lymphoma cells in the same inoculum. In vitro, H-2-deficient cells were more sensitive to killing by spleen cells from mice treated with interferon or natural killer-inducing agents. The presence of cold H-2-deficient cells did not activate the killing of H-2-positive cells, and H-2-positive cells did not inhibit killing of H-2-deficient cells. Such mixing experiments revealed a more efficient cold target inhibition by the H-2-deficient cells, although no difference was seen between these and the H-2-positive wild-type cells in target binding assays. When Thy-1.2+, nylon wool adherent or phagocytic populations were removed from normal spleen effectors, the difference in spontaneous cell-mediated cytotoxicity between the H-2-deficient and the H-2-positive cells persisted. This result was also obtained when spleen cell effectors from nude mice or asialo GM1+ effectors, positively enriched by fluorescence-activated cell sorter, were used. The results show that the selectivity in the rejection of H-2-deficient cells was not determined in the afferent arm alone. The present data fit with a previously proposed model where natural killer cells would bind equally well to both major histocompatibility complex class I negative and class I positive target cells, but only the latter would be able to present a postbinding inhibitory signal allowing them to escape killing which results in outgrowth in vivo and poor cold target competition in vitro.
从鼠淋巴瘤RBL-5中筛选出的H-2缺陷变体,最近显示与相应的H-2阳性野生型细胞系相比,在同基因小鼠中致瘤性较低。本研究聚焦于导致体内H-2缺陷细胞被特异性排斥的详细细胞相互作用。用混合肿瘤接种物进行的体内实验,测量肿瘤生长或快速清除情况,结果表明H-2阳性淋巴瘤细胞的存在并未抑制H-2缺陷细胞的排斥。相反,H-2缺陷细胞并未激活对H-2阳性细胞的排斥。即使在同一接种物中,H-2缺陷细胞与H-2阳性淋巴瘤细胞相比数量多出10倍,它们仍会被选择性清除。在体外,H-2缺陷细胞对用干扰素或天然杀伤诱导剂处理的小鼠的脾细胞杀伤更敏感。冷的H-2缺陷细胞的存在并未激活对H-2阳性细胞的杀伤,且H-2阳性细胞也未抑制对H-2缺陷细胞的杀伤。此类混合实验显示H-2缺陷细胞对冷靶标的抑制作用更有效,尽管在靶标结合试验中它们与H-2阳性野生型细胞之间未观察到差异。当从正常脾效应细胞中去除Thy-1.2+、尼龙毛黏附或吞噬细胞群体时,H-2缺陷细胞与H-2阳性细胞之间的自发细胞介导细胞毒性差异仍然存在。当使用裸鼠的脾细胞效应细胞或经荧光激活细胞分选仪阳性富集的去唾液酸GM1+效应细胞时,也得到了这一结果。结果表明,对H-2缺陷细胞排斥的选择性并非仅由传入臂决定。目前的数据符合先前提出的模型,即自然杀伤细胞与主要组织相容性复合体I类阴性和I类阳性靶细胞的结合能力相同,但只有后者能够呈现结合后抑制信号,使其逃避杀伤,从而在体内生长并在体外表现出较差的冷靶标竞争能力。